Skip to main content
. 2018 Apr 3;361:k1180. doi: 10.1136/bmj.k1180

Fig 4.

Fig 4

Kaplan-Meier survival probability plots (with 95% CI shaded) of branded drug product switchbacks over the follow-up period in exposure groups in the primary cohort